We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
Read MoreHide Full Article
Key Takeaways
Sanofi secured European Commission approval for Teizeild to delay progression to stage 3 T1D disease.
SNY-backed TN-10 phase II study showed median progression delayed to 48.4 months vs. 24.4 months with placebo.
Teizeild became the first disease-modifying type 1 diabetes therapy authorized in the EU following the nod.
Sanofi (SNY - Free Report) announced that the European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged eight years and older with stage 2 disease. The approval was expected as the Committee for Medicinal Products for Human Use of the European Medicines Agency had issued a positive opinion in November recommending the approval of Teizeild.
With this approval, Teizeild becomes the first T1D disease-modifying drug authorized in the European Union.
The drug is already approved in the United States and several other countries for delaying the onset of stage 3 T1D in adults and children aged eight years and older with stage 2 T1D. Sanofi markets the drug under the brand name of “Tzield” outside the European Union.
In the past year, SNY’s shares have declined 1.7% against the industry’s 21.9% rise.
Image Source: Zacks Investment Research
SNY’s Teizeild Approval Based on TN-10 Phase II Study
The European Commission’s approval is supported by positive data from the TN-10 phase II study, which included 76 participants aged eight to 45 years with stage 2 T1D. Participants were randomly given either Teizeild or a placebo for 14 days.
The study met its primary endpoint by demonstrating significant delays in progression from stage 2 T1D to stage 3 T1D. The median time to progression to stage 3 diabetes was 48.4 months in the Teizeild arm versus 24.4 months in the placebo arm. Moreover, 57% of patients treated with Teizeild remained in stage 2 compared with 28% in the placebo group, with fewer adverse events reported.
Teizeild was added to Sanofi’s portfolio in 2023, following its $2.9 billion acquisition of Provention Bio. The drug was originally developed by MacroGenics (MGNX - Free Report) . Provention Bio acquired this drug from MacroGenics under an asset purchase agreement signed in 2018.
Earlier this month, the FDA granted priority review to a regulatory filing seeking approval to expand Tzield’s use in the United States for individuals aged one year and older with stage 2 disease. The final decision is expected by April 29, 2026.
Tzield recorded global product sales of €47 million in the first nine months of 2025, up 33.3% at constant exchange rates, with €44 million coming from the United States.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 55% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters, with the negative average surprise being 20.21%.
Over the past 60 days, estimates for Indivior’s 2026 earnings per share have risen to $2.85 from $2.60. Indivior stock has rallied 208.3% over the past year.
Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
Key Takeaways
Sanofi (SNY - Free Report) announced that the European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged eight years and older with stage 2 disease. The approval was expected as the Committee for Medicinal Products for Human Use of the European Medicines Agency had issued a positive opinion in November recommending the approval of Teizeild.
With this approval, Teizeild becomes the first T1D disease-modifying drug authorized in the European Union.
The drug is already approved in the United States and several other countries for delaying the onset of stage 3 T1D in adults and children aged eight years and older with stage 2 T1D. Sanofi markets the drug under the brand name of “Tzield” outside the European Union.
In the past year, SNY’s shares have declined 1.7% against the industry’s 21.9% rise.
Image Source: Zacks Investment Research
SNY’s Teizeild Approval Based on TN-10 Phase II Study
The European Commission’s approval is supported by positive data from the TN-10 phase II study, which included 76 participants aged eight to 45 years with stage 2 T1D. Participants were randomly given either Teizeild or a placebo for 14 days.
The study met its primary endpoint by demonstrating significant delays in progression from stage 2 T1D to stage 3 T1D. The median time to progression to stage 3 diabetes was 48.4 months in the Teizeild arm versus 24.4 months in the placebo arm. Moreover, 57% of patients treated with Teizeild remained in stage 2 compared with 28% in the placebo group, with fewer adverse events reported.
Teizeild was added to Sanofi’s portfolio in 2023, following its $2.9 billion acquisition of Provention Bio. The drug was originally developed by MacroGenics (MGNX - Free Report) . Provention Bio acquired this drug from MacroGenics under an asset purchase agreement signed in 2018.
Earlier this month, the FDA granted priority review to a regulatory filing seeking approval to expand Tzield’s use in the United States for individuals aged one year and older with stage 2 disease. The final decision is expected by April 29, 2026.
Tzield recorded global product sales of €47 million in the first nine months of 2025, up 33.3% at constant exchange rates, with €44 million coming from the United States.
Sanofi’s Zacks Rank & Stocks to Consider
SNY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amicus Therapeutics (FOLD - Free Report) and Indivior (INDV - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 55% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters, with the negative average surprise being 20.21%.
Over the past 60 days, estimates for Indivior’s 2026 earnings per share have risen to $2.85 from $2.60. Indivior stock has rallied 208.3% over the past year.
Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.